Cancer Therapy Vol 3, page 483
Figure 3. Representative SELDI-TOF-MS spectra of urine obtained at baseline and 2 hours post-CPB from patients in the Control or ARF group. Figure shows proteins in the 5500-7500 kDa range. Marked enhancement of a 6.4 kDa species is noted in the ARF group at 2 hours post-CPB.
Figure 4. Representative SELDI-TOF-MS spectra of urine obtained at baseline and 2 hours post-CPB from patients in the Control or ARF group. Figure shows proteins in the 20,000-70,000 kDa range. Marked enhancement of 28.5, 33, 43, and 66 kDa species is noted in the ARF group at 2 hours postCPB.
Figure 5 . Overlay of representative SELDI-TOF-MS spectra of urine obtained at baseline and 2 hours post-CPB from patients in the ARF group. Marked enhancement of 28.5, 33, 43, and 66 kDa species is noted in the ARF group at 2 hours post-CPB, as highlighted by the arrows. The specific identity of these biomarkers is currently unknown. However, it is likely that the 28 kDa species may represent NGAL.
483